Promega, JA2222, TIM-3 Bioassay

Measure the Ability of Biologics to Block Immune Checkpoint Signals
The TIM-3 Bioassay is a bioluminescent reporter cell-based assay that overcomes the limitations of existing assays and can be used to measure the potency and stability of antibodies and other biologics targeting TIM-3. TIM-3 (CD366, HAVCR2) is an immune checkpoint receptor expressed on a subset of activated T cells, regulatory T cells (Tregs), macrophages and dendritic cells. TIM-3 has the capacity to inhibit or costimulate T-cell receptor (TCR) signaling in different in vitro systems.
The TIM-3 Bioassay consists of two cell lines:
TIM-3 Effector Cells: Human T cells genetically engineered to express human TIM-3 and a NanoLuc® luciferase reporter driven by T cell activation pathway-dependent response elements
TIM-3 Target Cells: MHCII-positive human cell line
When the two cell types are co-cultured, TIM-3 Target Cells provide low-level stimulation to the TIM-3 Effector Cells through the TCR. The combined stimulation of the TCR and TIM-3 induces promoter-mediated luciferase activation and luminescence. Adding a TIM-3 blocking antibody prevents TIM-3 signaling and reduces promoter-mediated luminescence.
The Control Ab, Anti-TIM-3, is a mouse anti-human TIM-3 antibody that shows blocking activity for TIM-3 with its ligands. It is intended for use as a control with the TIM-3 Bioassay, which can be used to measure the potency and stability of antibodies and other biologics designed to block the TIM-3 signaling.